TCV 309

Known as: TCV-309 
 

Topic mentions per year

Topic mentions per year

1991-2013
051019912013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Sepsis and organ failure remain the main cause of death on the ICU. Sepsis is characterized by a severe inflammatory response, in… (More)
Is this relevant?
1999
1999
We investigated the role of platelet-activating factor (PAF) as a priming signal for cytokine-induced neutrophil chemoattractant… (More)
Is this relevant?
1997
1997
BACKGROUND Ischemia-reperfusion injury is one of the major problems in organ transplantation. The role of platelet-activating… (More)
Is this relevant?
1996
1996
In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating… (More)
Is this relevant?
1994
1994
Platelet-activating factor (PAF) has been postulated to play a role in the pathogenesis of sepsis. Additionally, in vitro studies… (More)
Is this relevant?
1994
1994
The aim of this study was to evaluate: (1) the accumulation of leukocytes in the ileum and the lung during splanchnic artery… (More)
  • figure 2
  • figure 1
  • figure 5
  • figure 3
  • figure 4
Is this relevant?
1993
1993
OBJECTIVES The aims were to confirm that platelet activating factor is released during reperfusion after global ischaemia in… (More)
Is this relevant?
1993
1993
1. The present study was conducted in order to examine the effects of the platelet-activating factor (PAF) antagonist, TCV-309… (More)
Is this relevant?
1992
1992
Pharmacological profiles of a novel specific platelet activating factor (PAF) antagonist, TCV-309 (3-bromo-5-[N-phenyl-N-[2-[2… (More)
Is this relevant?
1992
1992
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension… (More)
Is this relevant?